Answers are grounded in this paper and cite their sources.
, it alleviated neurological deficits, brain edema, and histopathological changes, reduced inflammatory and oxidative stress markers, and promoted M2-like polarization. CXEO-LP@M2M combines cell membrane delivery and nano-carrier systems, showing stability, safety, and efficient brain targeting in the present models. The M2-like-microglia membrane modification was intended to enhance microglial recognition and uptake, while nasal delivery may help bypass the blood-brain barrier. This study highlights CXEO-LP@M2M as a potential early intervention/protective strategy for ischemic stroke by combining biomimetic delivery with the modulation of neuroinflammation.
No takes yet. Share an insight, caveat, or question.
Long et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: